WASHINGTON, D.C. – The Global CEO Initiative on Alzheimer’s Disease (CEOi) today announced that Drew Holzapfel, will join the CEOi as Executive Director. With his addition to the CEOi, Mr. Holzapfel brings a wealth of experience from positions in global and U.S. biotechnology, pharmaceutical and government organizations to the fight against Alzheimer’s disease.
“We’re immensely pleased to have Drew join the initiative,” said George Vradenburg, Chairman of USAgainstAlzheimer’s and convener of CEOi. “Drew brings a strong track record of advancing innovative programs to combat Alzheimer’s through public-private collaborations in the U.S. and abroad. This is the embodiment of what the CEOi is about and the key path towards stopping Alzheimer’s within the decade.”
The CEOi is a newly-formed private-sector initiative designed to collaborate with the public sector, non-profit community and academia, as a response to the call of political leaders for industry to help address this unprecedented global health, societal and fiscal threat posed by Alzheimer’s disease.
“The Global CEO Initiative on Alzheimer’s Disease marks an important step in creating much-needed innovations in prevention, treatment, and care of Alzheimer’s disease. The initiative takes a unique approach to advancing Alzheimer’s prevention by convening leading companies across diverse sectors. I couldn’t be more excited to join this bold effort and the fight to stop Alzheimer’s,” said Holzapfel.
Mr. Holzapfel has been in the Alzheimer’s and Neuroscience fields for over a decade. Most recently, he was at Pfizer, where he led commercial strategy efforts around the company’s Alzheimer’s program and advanced Alzheimer’s and aging issues through his work with advocacy with international organizations, non-governmental organizations, non-profits and other key stakeholders. Mr. Holzapfel earned his Bachelor’s degree from Emory University and a Masters of Business Administration from The University of Maryland Smith School of Business.
The founding members of the CEOi include biopharmaceutical and healthcare companies AC Immune, Eli Lilly and Company, Janssen Research & Development, LLC, Merck (known as MSD outside of the U.S. and Canada), Pfizer, Inc. Sanofi and Nestlé Health Science; financial services provider Bank of America Merrill Lynch; healthcare solutions company GE Healthcare; and Banner Health, a large multi-state, not-for-profit, healthcare system.
The Global CEO Initiative on Alzheimer’s Disease (CEOi) is an organization of private-sector leaders who have joined together to provide business leadership in the fight against Alzheimer’s. The CEO Initiative seeks to partner with public leaders to transform the disease from a social, health, and economic crisis into an opportunity for healthy aging and innovation in research and care. The CEO Initiative believes that, during this era of aging populations, it will take visionary, coordinated, goal-oriented leadership of public and private leaders working together to solve our greatest challenges. www.ceoalzheimersinitiative.